Oxybutynin

Nocturia, Urinary Bladder, Overactive, Neurological Disorders + 8 more

Treatment

20 Active Studies for Oxybutynin

What is Oxybutynin

Oxybutynin

The Generic name of this drug

Treatment Summary

Oxybutynin, also known as Ditropan XL, is a medication used to treat overactive bladder. Overactive bladder is a condition that causes frequent urination due to urinary urgency and frequency. This drug was approved by the FDA in 1975 and has been tested for safety and effectiveness. Oxybutynin is often the first medication prescribed to patients with overactive bladder and can help improve their quality of life.

Ditropan

is the brand name

image of different drug pills on a surface

Oxybutynin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ditropan

Oxybutynin

1975

256

Effectiveness

How Oxybutynin Affects Patients

Oxybutynin helps to reduce the uncomfortable symptoms of overactive bladder, such as frequent or urgent urination. It does this by blocking certain receptors in the bladder. However, there is a risk of angioedema (swelling) and anticholinergic effects (hallucinations, confusion, agitation, and drowsiness). If angioedema is suspected, it is important to stop taking oxybutynin right away and seek medical help. It is also best to avoid operating heavy machinery until you know how your body will respond to oxybutynin. The dose may need to be adjusted depending on your response

How Oxybutynin works in the body

Oxybutynin works to relax the bladder muscles and help increase the amount of urine it can hold. It does this by blocking the effects of a chemical called acetylcholine, which is responsible for muscle contractions. Oxybutynin's active ingredient, N-desethyloxybutynin, competes with acetylcholine at the postganglionic type 1, 2, and 3 muscarinic receptors. This prevents acetylcholine from carrying out its muscle contraction function, resulting in a relaxed bladder and less frequent urges to urinate.

When to interrupt dosage

The recommended dosage of Oxybutynin is contingent upon the diagnosed condition, including Neurological Disorders, Foley Catheterization and Nocturia. The dosage amount depends on the delivery method (e.g. Tablet, extended release or Patch) noted in the table below.

Condition

Dosage

Administration

Spinal Dysraphism

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Urinary Bladder, Overactive

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Neurological Disorders

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

increased frequency of urination

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Foley Catheterization

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Longterm Indwelling Ureteral Stent

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Nocturia

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Bladder Spasms

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Urinary Urgency

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Urinary Incontinence, Urge

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Overactive Bladder Syndrome

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Warnings

Oxybutynin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Oxybutynin may interact with Pulse Frequency

Urinary Retention

Do Not Combine

uncontrolled narrow-angle glaucoma

Do Not Combine

Gastric Retention

Do Not Combine

There are 20 known major drug interactions with Oxybutynin.

Common Oxybutynin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Oxybutynin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Oxybutynin.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Oxybutynin is combined with Aclidinium.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Oxybutynin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Oxybutynin.

Oxybutynin Toxicity & Overdose Risk

The most toxic dose of oxybutynin for rats is 460 mg/kg. If a person overdoses on oxybutynin, they may experience symptoms such as excessive excitement, fever, irregular heartbeat, difficulty urinating, breathing problems, paralysis, and even a coma. In two reported cases of an overdose involving 100 mg of oxybutynin and alcohol consumption, the patients were treated with supportive care and made a full recovery. Activated charcoal and a cathartic agent should be administered immediately to reduce the effects of the overdose.

image of a doctor in a lab doing drug, clinical research

Oxybutynin Novel Uses: Which Conditions Have a Clinical Trial Featuring Oxybutynin?

79 active clinical trials are currently being conducted to analyze the potential of Oxybutynin in resolving Overactive Bladder Syndrome, Foley Catheterization and Neurological Disorders.

Condition

Clinical Trials

Trial Phases

Nocturia

4 Actively Recruiting

Not Applicable, Phase 4

Bladder Spasms

1 Actively Recruiting

Phase 2

Spinal Dysraphism

0 Actively Recruiting

Urinary Incontinence, Urge

5 Actively Recruiting

Not Applicable, Phase 4

Foley Catheterization

0 Actively Recruiting

Urinary Urgency

2 Actively Recruiting

Not Applicable

Urinary Bladder, Overactive

0 Actively Recruiting

Overactive Bladder Syndrome

26 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 2, Phase 3

Longterm Indwelling Ureteral Stent

0 Actively Recruiting

Neurological Disorders

7 Actively Recruiting

Not Applicable, Phase 2

increased frequency of urination

3 Actively Recruiting

Not Applicable

Oxybutynin Reviews: What are patients saying about Oxybutynin?

5

Patient Review

8/21/2022

Oxybutynin for Problems with Bladder Control

I was hesitant to try this medication, but after four months I can say that it works better and is much more affordable than the other options out there.

5

Patient Review

2/23/2019

Oxybutynin for A Condition of Bladder Dysfunction from Nerve Disorder

Almost immediately after starting this medication, I developed awful itching on my arms and hands. It was like it started in one spot and then quickly got worse. The worst part is that nothing helped - not evenBenadryl or other creams. So, unfortunately, I'm going to have to stop taking it because of the skin irritation. Hopefully I'll be able to find something else that will help with my bladder issues.

5

Patient Review

3/20/2017

Oxybutynin for Frequent Urination

4.3

Patient Review

12/4/2019

Oxybutynin for Overactive Bladder

I had three seizures in quick succession after taking just two doses of this medication. There are much better options out there, so please avoid this one if possible. I was taken to the ER three times and it was an overall terrible experience. The paramedics told my mom that they weren't sure how I survived. I still suffer from PTSD today because of it.

4.3

Patient Review

10/8/2019

Oxybutynin for Overactive Bladder

It's only been three weeks, but I'm already having to urinate more frequently. So far the results haven't been great, but I know it could take a while for the drug to really kick in.

3.3

Patient Review

6/18/2018

Oxybutynin for Problems with Bladder Control

The medication caused really uncomfortable side effects like dry mouth, dizziness, and fatigue.

3

Patient Review

11/1/2021

Oxybutynin for Overactive Bladder

I had some pretty serious eye trouble after just a few days of taking this medication. I stopped immediately and am seeing a specialist today.

2.3

Patient Review

3/24/2018

Oxybutynin for Overactive Bladder

I only take this medication when my bladder acts up, and every time I take it I immediately feel better. I have never noticed any side effects and I have been taking them for 5 months now.

2

Patient Review

3/27/2019

Oxybutynin for Frequent Urination

This medication has been a godsend for me. I have diabetic neuropathy, which causes incontinence and an inability to sense when my bladder is full. This often leads to accidents. Since taking this drug, however, I haven't had any accidents or side effects. I'm very pleased with the results so far.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about oxybutynin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the most common side effects of oxybutynin?

"Dry mouth, blurred vision, dry eyes, nose, or skin, stomach pain, constipation, diarrhea, nausea, and heartburn are all potential side effects of this medication."

Answered by AI

Should I take oxybutynin at night?

"Immediate-release oxybutynin is usually taken three or four times per day, unless it is only being used for night-time urinary incontinence, in which case only one dose is taken at night."

Answered by AI

Is oxybutynin a high risk medication?

"The medication oxybutynin, which is commonly used to treat OAB (a combination of urinary tract symptoms including frequent urination and the inability to control urination), may be harmful to brain health and may increase the risk of dementia, according to research."

Answered by AI

What exactly does oxybutynin do?

"What is oxybutynin and how does it work? Oxybutynin is a medicine that relaxes the muscle in the wall of the bladder, increasing the volume of urine the bladder can hold and helping to control the release of urine."

Answered by AI

Clinical Trials for Oxybutynin

Image of Stanford Medicine Department of Obstetrics & Gynecology in Palo Alto, United States.

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder

22 - 80
Female
Palo Alto, CA

The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.

Waitlist Available
Device

Stanford Medicine Department of Obstetrics & Gynecology (+10 Sites)

Mickey Karram, MD

InMode MD Ltd.

Have you considered Oxybutynin clinical trials?

We made a collection of clinical trials featuring Oxybutynin, we think they might fit your search criteria.
Go to Trials

Have you considered Oxybutynin clinical trials?

We made a collection of clinical trials featuring Oxybutynin, we think they might fit your search criteria.
Go to Trials
Image of Rossignol Medical Center in Phoenix, United States.

Photobiomodulation for Autism

4 - 12
All Sexes
Phoenix, AZ

For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical practice of treating autism. At the beginning, at five weeks, and at the end of study, the clinician will complete the CARS-2, SRS, CGI, and a caregiver interview; additionally, questionnaires will be administered to caregivers during one of the 1-hour weekly treatment sessions.

Phase 2
Recruiting

Rossignol Medical Center

Richard E Frye, M.D., Ph.D

Image of Mickey Karram MD in Corona Del Mar, United States.

Nerve Ablation for Overactive Bladder

21 - 80
Female
Corona Del Mar, CA

The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder The main questions it aims to answer are: •Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. \[Time Frame: 3 months\] Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis. Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment.

Waitlist Available
Has No Placebo

Mickey Karram MD (+2 Sites)

Mickey Karram, MD

InMode MD Ltd.

Have you considered Oxybutynin clinical trials?

We made a collection of clinical trials featuring Oxybutynin, we think they might fit your search criteria.
Go to Trials